Merck KGaA
https://www.merckgroup.com/en
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Merck KGaA
Sanofi’s MS Candidate Tolebrutinib On Clinical Hold Following Liver Toxicities
The firm’s BTK inhibitor tolebrutinib has been put on clinical hold by the US FDA following liver injuries, but advanced trials should continue as normal since most patients have passed the 60-day mark.
4D Pharma Is Latest Biotech Casualty After Creditor Calls Time
The UK biotech looks to have reached the end of the road, despite some encouraging signs from its microbiome-based pipeline.
Daiichi Eyes First-Line AML Filings For Vanflyta On Positive Data
Daiichi Sankyo is aiming to overcome past US and EU setbacks for its FLT3 inhibitor Vanflyta with planned filings for first-line AML on the back of positive new Phase III data.
Cardio Catch-Up: Gel For Fixing Heart Attacks, ‘Uncaged’ Coronary Stents, And More
Medtech Insight’s Cardiovascular Catch-Up highlights recent news on cardiovascular tech innovations in the last two months. Part II of this month’s update includes innovative research and development news from smaller companies and research labs that you may have missed.
Company Information
- Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Pharmaceuticals
- Drug Delivery
- Nutraceuticals
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
- Other Names / Subsidiaries
-
- Acadiana Ventures Inc.
- Allergopharma Joachim Ganzer KG
- AmpTec GmbH
- Asceneuron
- Chord Therapeutics SA
- EMD Pharmaceuticals
- Grzybowski Scientific Inventions (GSI)
- Intermolecular Inc
- JRH Biosciences
- Merck Hoei Ltd.
- Millipore
- MilliporeSigma
- Ormet Circuts Inc.
- Serono
- EMD Serono, Inc.
- Sigma-Aldrich
- Versum Materials, Inc.